P-034 Colloidosmes : Emerging Novel Carrier for Delivery of Insulin to Colon

Shilpi S.¹ and Jain SK.² ¹ Pharm Res Lab, Pharm Sc, ² Dr. Hari Singh Gour Univ, Sagar, India, Email: shilpisatish@gmail.com



INTRODUCTION AND OBJECTIVES

The objective of the study is to securely target insulin to the colon through a novel carrier colloidosomes for effective management of blood glucose level. Colloidosomes efficiently encapsulate insulin in their gel aqueous core as well as their surface colloidal spherical particle layer helps in controlling the release of insulin in the colon. Insulin is released from colloidosomes and absorbed in the colon which reduce blood glucose level in albino rabbit.

Efficient encapsulation of active ingredients such as drugs, proteins, vitamins, or even living cells is becoming increasingly important for a wide variety of applications and technologies, ranging from drug delivery to biomedical applications (Chaikof 1999). Encapsulation of bioactive macromolecules, especially of peptides and proteins, has received immense attention in recent years. The majority of therapeutic peptides and proteins are administered via the parenteral route presents numerous limitations including patient discomfort and other. To overcome these drawbacks, alternative administrative route, such as oral route have been investigated (Shah 2002) but on oral administration of protein and peptide drug, degradation is occur in upper part of GIT.

Colloidosomes are microcapsules with shells consisting of coagulated or partially fused colloid particles (Velev 1997, Dinsmore 2002). Recently, it was recognized that the colloidosome membranes offer great potential in controlling the permeability of entrapped species. Their major advantage is that the interstices or pore size can be varied by choosing particles of an appropriate size and by controlling their degree of fusion, which can find various applications for the development of novel drug and vaccine delivery vehicles (Velev 1997, Kumaraswamy 2002, Fang 2002, Dinsmore 2002, Cayre 2004) have prepared colloidosomes by the assembly of latex particles into shells around water-in-oil emulsion drops, followed by thermal fusion of the particles in the shell and centrifugal transfer into water through a planar oil–water interface.

The present study is aimed at developing colloidosomes for the release of insulin to the colon in such a way that the core encapsulating insulin is coated with polymeric nanoparticles. These colloidosomes were administered to rabbit and seem to be unaffected in the upper part of GIT. Colloidosomes disperse in the colon where insulin gets released from the core of colloidal nanoparticles. Thereafter, this carrier system was also evaluated for its therapeutic efficacy in vivo for the management of diabetes mellitus in albino rabbit model.

MATERIALS AND METHOD

Insulin was procured as a gift sample from M/s Torrent Pharmaceuticals Ltd., Ahmedabad, India. Poly Methyl Methacrylate (PMMA) purchased from SIGMA, Tetrahydrofuron (THF), Sunflower oil, Chitosan, pepsin, trypsin and α -chymotrypsin were obtained from HiMedia, Mumbai, India. Glucose estimation kit (Glucose GOD-POD kit, Bayers diagnostics) was purchased from Bayer's diagnostics. All other chemicals and solvents were of analytical grade.

Colloidosomes were prepared in two steps first the preparation of nanoparticles (NPs) of PMMA, which was based on reprecipitation method, reported by Yabu (2005) and second step is the integration of colloidosomal assembly. Colloidosomes were prepared by emulsification method which was reported by Weitz (2002) with suitable modifications.

The size of NP's as well as colloidosomes were determined using a Zetasizer (Malvern Instruments, UK) after appropriate dilution in distilled water. Shape and surface morphology of nanoparticles and colloidosomes were studied using SEM shown in fig. 1 A & B, respectively. The average particle size and polydispersity index of the colloidosomes were determined by optical microscopy using a calibrated occulometer. *In vitro* drug release of insulin was carried in simulated GIT fluids with and without rat ceacal content (fig. 2). *In vivo* antidiabetic study carried by estimating plasma glucose level using glucoseoxidase method (Glucose GOD-POD kit, Bayers diagnostics) shown in fig. 3.




Figure 1 : SEM photomicrograph of prepared nanoparticles (A) and colloidosomes (B).




Figure 2 : In vitro drug release profile of insulin from colloidosomes [ILC2] in simulated GIT fluids containing different concentrations of Rat Caecal Content (RCC) (Mean \pm S.D., n=6).




Figure 3 : Plasma concentration profile of glucose after oral administration in different dosage forms. [SCI: Subcutaneous insulin, IPS: Insulin PBS solution, ILC: Insulin loaded colloidosomes (ILC1-ILC3), BC: Blank colloidosomes]. [Results are expressed as mean \pm S.D. (n=6); compared to control; Blank colloidosomes]

RESULTS AND DISCUSSION

Prepared nanoparticles were found in spherical shape with average size 257.20 ± 0.9 nm having small polydispersity index (0.074). In SEM photographs it is observed that prepared nanoparticles were spherical in shape. The average size of colloidosomes was found to 1. be $50.4\pm1.2 \mu$ m. The encapsulation efficiency was found to be $69.16\pm1.6\%$. Colloidosomes showed a matrix diffusion controlled first order release with 70–80% release in 24 h. A significantly prolonged decline of the plasma glucose level was obtained over 10 h after administration of the insulin-loaded colloidosomes at a dose of 100 IU/kg of body weight.

CONCLUSION

The nanoparticles were found to protect entrapped insulin against gut proteases. Colloidosomes showed a release profile that was suitable for oral delivery systems of proteins. *In vivo* results indicate that oral delivery of insulin loaded colloidosomes shows considerable promise in complimenting the therapy of diabetes. This is apparent from the exciting results in diabetic rats with significant blood glucose reduction for prolonged period. This is the first report of insulin loaded colloidosome system, and a successful carrier of the oral insulin strategies tried. However, the limitation of this system, such as optimization of drug release in a more controlled fashion is a compromise to develop protein friendly carriers. These results warrant further optimization and elaborate investigations in various *in vivo* models to develop a successful oral delivery platform.

Therefore, it is conclude that colloidosomes as drug delivery vehicle containing insulin can be successfully exploited for the treatment of diabetes mellitus.

REFERENCES

- Cayre OJ. et al. (2004) Fabrication of novel colloidosome microcapsules with gelled aqueous cores. J. Mater. Chem. 14 3351 – 3355.
- Chaikof EL. (1999) Engineering and material considerations in islet cell transplantation. Annual Rev Biomed Eng. 1 103-127.
- Dinsmore AD. et al. (2002) *Colloidosomes: selectively permeable capsules composed of Colloidal Particles.* Science. 298 1006-1009.
- Fang M. et al. (2002) *Magnetic Bio/Nanoreactor Nanoparticles*. Langmuir. 18 6338-6344.
- Kumaraswamy G. et al. (2002) *Photonic Materials* from self-assembly of Tolerant core-shell coated colloids. Langmuir. 18 4150-4154.
- Shah RB. et al. (2002) Oral delivery of proteins: progress and prognostication. Crit Rev Ther Drug Carrier Syst. 19(2) 135-69.
- Velev OD. et al. (1997) Assembly of Latex particles by using emulsion droplets Reverse (Water in Oil) system. Langmuir. 13 1856-1959G.
- Weitz DA. et al. (2002) Colloidosomes: selectively permeable capsules composed of Colloidal Particles. Science. 298 1006-1009.
- Yabu H. et al. (2005) Single-Step Fabrication of Transparent Superhydrophobic Porous Polymer Films, Chem. Mater. 17 (21) 5231–5234.

ACKNOWLEDGEMENT

The authors wish to extend their gratitude to M/s Torrent Pharmaceuticals Ltd., Ahmedabad, India for supplying Insulin as a gift sample. One of the authors is thankful to UGC, New Delhi, India for providing financial assistance (JRF). Authors are also grateful to Indian Institute of Technology, Kanpur for providing Scanning Electron Microscopy facility.